Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aquinox Begins COPD Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Aquinox Begins COPD Trial

Tests anti-inflammatory agent in exacerbation of COPD

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Aquinox Pharmaceuticals has begun dosing patients in a Phase II trial of its lead clinical candidate, AQX-1125, a SHIP1 activator, for the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). The multinational trial is being conducted at outpatient clinics across northern and central Europe and will evaluate the safety and efficacy of AQX-1125 in approximately 350-400 unstable moderate to severe COPD patients with a history of frequent exacerbations. The company has received regulatory approval for the trial in four countries and anticipates completion with top-line results occurring before the end of 2014.

Most marketed therapies for COPD are inhaled drugs directed towards managing symptoms by dilating narrowed airways (bronchodilators), often in combination with inhaled corticosteroids. These inhaled therapies, while demonstrating the ability to ease breathing, have modest effects on slowing the progression of COPD or reducing exacerbations. The most widely prescribed treatment for an acute exacerbation is a combination of antibiotics and oral corticosteroids but they can only be used for short duration leaving patients susceptible to secondary exacerbations. The company is developing AQX-1125 to provide new anti-inflammatory agents with reduced side effects that can be used for longer duration to resolve and prevent exacerbations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics